and rightly so if you look at pages 17 and 18 (regarding projections for its likely blockbuster moxduo) of their recent corporate presentation. on virtually all fronts, the MoxDuo combination significantly outperforms oxycodone and morphine (and percocet) and will, IMHO, introduce a new std of pain care once approved.
its CNS drug pipeline is not too shabby either.
the low number of shares circa 75M adds spice.
interest rising
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)